COVID-19 Funding Opportunities

I. Biomedical Advanced Research and Development Authority (BARDA)
BARDA has updated its Broad Agency Announcements (BAAs) to focus exclusively on addressing the COVID-19 threat. BARDA, with a total budget of $512 Million, is seeking proposals through the following mechanisms:

**View Solicitation**

**Topic:** Products to diagnose, prevent or treat novel coronavirus infections
**Due Date:** Rolling, through 10/31/2020
**Budget:** Unlimited

**Division of Research, Innovation & Ventures (DRIVe) BAA**

**View Solicitation**

**Topics:** Diagnostic assays, screening and model development, vaccines, advanced manufacturing.
**Due Date:** Abstract submissions due by 5PM ET on 6/30/2020.
**Budget:** $750,000

II. National Institutes of Health (NIH)
The National Institute of Neurological Disease and Stroke (NINDS) has released a Notice of Special Interest (NOSI) for COVID-19 related research

NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the novel coronavirus SARS-CoV-2 (previously termed 2019-nCoV) and its associated illness, COVID-19.

**View Solicitation**

**Topic:** NINDS is especially interested in developing systems to collect data on the neurologic effects of COVID-19 infection in patients requiring intensive care and less severely affected individuals seen by health care practitioners
**Due Date:** Rolling, through 5/9/2020
**Budget:** Not Specified

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NOSI: Urgent Competitive Revision Supplements on Coronavirus Disease (COVID-19) within the Mission of NIDDK

**View Solicitation**

**Topic:** Direct action of the virus on kidney, gastrointestinal tract function, and the endocrine/metabolic system, and the collection of biosamples that will inform the understanding of renal, gastrointestinal, and endocrine/metabolic sequelae of viral infection.
**Due Date:** 6/2/20
**Budget:** Lesser of current year direct cost budget or $500,000

National Heart, Lung, Blood Institute (NHLBI)

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

**View Solicitation**

**Topic:** NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.
**Due Date:** Rolling, through 10/5/2020
**Budget:** Not specified
National Institute of General Medical Sciences (NIGMS)
NOSI: Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

View Solicitation

Topic: Predictive models for the spread of SARS-CoV-2 and other related infectious agents *(all relevant grants).* Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection; rapid development of potential therapeutic agents for COVID-19 *(SBIR/STTR grants only).*

Due Date: Rolling, through 2/6/2021
Budget: Not Specified

National Institute of Allergy and Infectious Diseases (NIAID)
NOSI: Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

View Solicitation

Topic: Viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

Due Date: Rolling, through 3/25/2021
Budget: Not specified

National Institute of Drug Abuse (NIDA)
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

View Solicitation

Topic: NIDA is interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

Due Date: Rolling, through 3/31/2021
Budget: Maximum of $100,000 direct costs per year for 2 years. Higher budgets may be considered with justification.

III. National Science Foundation (NSF)
Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19

NSF is seeking Phase I SBIR/STTR proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis.

View Letter

Topics: Artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations.

Due Date: Rolling, Project Pitch submission required
Budget: $225,000

Dear Colleague Letter on the Coronavirus

View Letter

The NSF encourages investigators to use existing NSF funding mechanisms to submit proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

For proposals of up to $200K, NSF encourages using the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency.
Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)

The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.

IV. U.S. Department of Agriculture (USDA)
Small Business Innovation Research (SBIR)
Topics: Projects must fit the topics covered by the specific program that you are applying under. All projects must include “COVID-19 Rapid Response” in the title.

Rapid Response to Novel Coronavirus (SARS-CoV-2) Impacts Across Food and Agricultural Systems Program Area
Topics: Develop and deploy rapid, reliable, and readily adoptable strategies across the food and agriculture enterprise in response to the COVID-19 pandemic. These strategies should mitigate urgent threats from the COVID-19 virus (SARS-CoV-2) and ensure the availability of an accessible, safe, nutritious, and abundant food supply. Can be local, regional or national in scope and should employ interdisciplinary teams.

National Institute of Food and Agriculture (NIFA)
Agriculture and Food Research Initiative (AFRI)
In response to the current need for more COVID-19 information, certain NIFA programs will allow submission of COVID-19 relevant projects outside of their normal deadlines.

V. Other US Funding Agencies
Medical CBRN Defense Consortium (MCDC)
Request for Information (RFI) – CoV Pandemic Response
MCDC is requesting proposals regarding rapidly deployable (1-6 months) products and technologies to combat the current pandemic. Longer-term solutions are not requested in this RFI.
Topic: COVID-19-related Diagnostics/Monitoring, Surveillance, Information Systems for Point of Care, Therapeutics, Prophylactics, Clinical Trials

Due Date: 5/31/2020
Budget: Not Specified

grants.cfaes.ohio-state.edu
gdsu@osu.edu
Deutsche Forschungsgemeinschaft (German Research Foundation)

View Solicitation (English)

Topics: Prevention, early detection, containment and investigation of the causes, impacts and management of epidemics and pandemics
Due Date: Letter of Intent – 7/1/20; Full Proposal – 9/1/20
Budget: Not Specified

Coalition for Epidemic Preparedness Innovation (CEPI)

Multi-purpose platform technologies for rapid response against emerging infectious diseases

View Solicitations

Topic: Vaccine and adaptive epidemic response platform development
Due Date: Expressions of Interest (EOIs) will be accepted on a rolling basis until 10/14/2020.
Budget: Not specified

Fast Grants

Fast grants are available exclusively to PIs at academic institutions already working on COVID-19 related projects that could help with the pandemic within the next six months.

View Solicitation

Topic: All COVID-19 related science
Due Date: Rolling, award decisions made in 48 hours
Budget: $10,000 - $500,000

ARPA-E SMARTFARM

Systems for Monitoring and Analytics for Renewable Transportation Fuels from Agricultural Resources and Management (SMARTFARM), to develop innovative new technologies for measuring emissions from agricultural feedstock production.

SMARTFARM projects will work to bridge the data gap in the biofuel supply chain by funding technologies that can replace national averages and emissions factors for feedstock-related emissions with field-level estimates. These technologies will work to reliably, accurately, and cost-effectively quantify feedstock production lifecycle emissions at the field level (i.e., scalable to >80 acres). If successful, feedstock producers will be able to leverage new, data-driven market incentives to catalyze efficiency improvements in feedstock production and carbon management, reducing annual U.S. emissions.

View Solicitations
Due Date: 6/23/20
Budget: Not specified

Wellcome, Bill & Melinda Gates Foundation, and Mastercard

The Bill & Melinda Gates Foundation, Wellcome, and Mastercard have committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments.

View Solicitations

Topics: (1) Identifying candidate compounds by testing approved drugs for activity against COVID-19, screening libraries of compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies. (2) Developing drugs or monoclonal antibodies that pass initial screening. Scaling up production and commercialization of successful drugs and monoclonal antibodies.
Due Date: Not specified
Budget: Not specified